VolitionRx appoints Timothy Still as Chairman, effective November 6, 2024

VOLITIONRX LTD

Timothy Still appointed non-executive Chairman and director of VolitionRx; board expanded to 8 members.
Still has 35+ years in diagnostics, most recently President/CEO of Sense Biodetection (merged with Sherlock).
Compensation includes $30K/quarter retainer, 400K time-vested RSUs, and 1M performance-based RSUs tied to $2.50/$5.00 stock price targets.
Annual RSU grant of 300K shares contingent on corporate goals, subject to share availability under incentive plans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.